Prostafexin® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing prostate size. First, Prostafexin® specifically inhibits prostate 5α-reductase type 2.
Prostafexin® weakly targets androgen receptor (AR) and blocks prostatic development. Prostafexin® also has component which targets The Mammalian Target of Rapamycin (mTOR) kinase. mTOR has been shown to control prostate cell growth, proliferation and energy metabolism. Finally, Prostafexin® potentiates the action of dutasteride/tamsulosin, thus, reducing the time for disease burden.
MyoFibrox® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing uterine size. First, MyoFibrox ® weakly inhibits nuclear receptor subfamily 3, group C, member 3 (progesterone receptor) and estrogen receptor (ER).
Atxilox® is a polyherbal formulation exhibiting varying mechanism of action. First, Atxilox® inhibits The Mammalian Target of Rapamycin (mTOR) kinase.
Metaxin® modulates Epithelial-Mesenchymal Transition (EMT), whereas tumour cells loose adhesion to the primary tumor and extracellular matrix (ECM) promoted by proteolytic degradation of the ECM by enzymes like matrix metalloproteinases (MMPs); and the activation of signaling pathways that promote cell motility and survival. Broadly, Metaxin® has two mechanisms of action.
